Antibodies

BHQ880 (anti-DKK1) is a humanized monoclonal antibody targeting Wnt antagonist Dickkopf-1 (DKK1). It binds to and inhibits DKK1, enhancing signaling through the Wnt pathway, which result in osteoblast differentiation and activation within the bone

BHQ880 (anti-DKK1) is a humanized monoclonal antibody targeting Wnt antagonist Dickkopf-1 (DKK1). It binds to and inhibits DKK1, enhancing signaling through the Wnt pathway, which result in osteoblast differentiation and activation within the bone

BHQ880 (anti-DKK1) is a humanized monoclonal antibody targeting Wnt antagonist Dickkopf-1 (DKK1). It binds to and inhibits DKK1, enhancing signaling through the Wnt pathway, which result in osteoblast differentiation and activation within the bone

Birtamimab (anti-Amyloid Alpha) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab (anti-Amyloid Alpha) can be used for the research of light chain amyloidosis.

Birtamimab (anti-Amyloid Alpha) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab (anti-Amyloid Alpha) can be used for the research of light chain amyloidosis.

Birtamimab (anti-Amyloid Alpha) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab (anti-Amyloid Alpha) can be used for the research of light chain amyloidosis.

Birtamimab (anti-Amyloid Alpha) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab (anti-Amyloid Alpha) can be used for the research of light chain amyloidosis.

Burosumab is a human fibroblast growth factor 23 (FGF23) neutralizing antibody that can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 0.01EU/μg

Burosumab is a human fibroblast growth factor 23 (FGF23) neutralizing antibody that can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 0.01EU/μg

Burosumab is a human fibroblast growth factor 23 (FGF23) neutralizing antibody that can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 0.01EU/μg

Burosumab is a human fibroblast growth factor 23 (FGF23) neutralizing antibody that can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 0.01EU/μg

CSL346 (anti-VEGFB) is an antibody targeting VEGFA.